News

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

As you might know, Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) just kicked off its latest second-quarter results ...
Zacks.com on MSN3d

Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
American Association of Individual Investors3d

Which Is a Better Investment, ADMA Biologics, Inc. or Amicus Therapeutics, Inc. Stock?

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...
Kalkine Media4d

XTX Topco Expands Stake in Amicus Therapeutics, Inc.

Highlights,XTX Topco Ltd significantly increased its position in Amicus Therapeutics during the first quarter,Shares of ...

Amicus Therapeutics Reports Strong Growth Amid Strategic Advances

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.
Kalkine Media4d

Assetmark Inc. Scales Down Stake in Amicus Therapeutics Amid Strategic Portfolio Rebalancing

Assetmark Inc. Scales Down Stake in Amicus Therapeutics Amid Strategic Portfolio Rebalancing | S&P 500 Futures Tracker ...

Amicus (FOLD) Q2 Revenue Jumps 22%

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Clinical Progress In Rare Disease Signals Long-Term Revenue Potential For Innovators - Financial News Media

Chronic rare diseases are becoming a major challenge for the aging population in the United States. As life expectancy rises, healthcare needs become more complex, especially for conditions that are ...